Oxygen Therapy for Retinal Ischemia

The investigators will be using nocturnal normobaric hyperoxia therapy in patients with diagnoses of conditions related to retinal ischemia.

Lead sponsor: Beth Israel Deaconess Medical Center•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

Not Yet RecruitingNA

Ambulatory Stroke Unit Treatment for Elderly Patients

NCT07420374 · Ischemic Stroke, Transient Ischemic Attack (TIA), and more

COMPLETEDNA

Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning in Patients With Type 1 Diabetes

NCT03906383 · Retinal Ischemia, Diabetes Complications, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 9, 2020Terms

Trial snapshot

StatusWITHDRAWN

PhasePHASE4

Enrollment—

Start dateNov 2018

Last updatedMar 9, 2020

Condition

Retinal Ischemia

Locations shown

Beth Israel Deaconess Medical Center

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 9, 2020Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions